Screening for Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in New Zealand.

Show simple item record McKeage, Mark en Tin Tin, Sandar en Khwaounjoo, Prashannata en Sheath, Karen en Dixon-McIver, Amanda en Ng, Daniel en Sullivan, Richard en Cameron, Laird en Shepherd, Philip en Laking, George Robert en Kingston, Nicola en Strauss, Magreet en Lewis, Christopher en Elwood, James en Love, Donald en 2020-06-09T22:15:39Z en 2019-07-18 en
dc.identifier.issn 1444-0903 en
dc.identifier.uri en
dc.description.abstract BACKGROUND:Lung cancer is a major cause of death in New Zealand. In recent years, targeted therapies have improved outcomes. AIM:To determine the uptake of ALK testing, and the prevalence, demographic profile and outcomes of ALK-positive NSCLC, in NZ, where no national ALK-testing guidelines or subsidized ALK tyrosine kinase inhibitor (TKI) therapies are available. METHODS:A population-based observational study reviewed databases to identify patients presenting with nonsquamous NSCLC over 6.5 years in northern NZ. We report the proportion tested for ALK gene rearrangements and the results. NSCLC samples tested by Fluorescence In Situ Hybridisation (FISH) were retested by Next Generation Sequencing (NGS) and ALK immunohistochemistry (IHC). A survival analysis compared ALK-positive patients treated or not treated with ALK TKI therapy. RESULTS:From a total of 3130 patients diagnosed with nonsquamous NSCLC, 407 (13%) were tested for ALK gene rearrangements, and patient selection was variable and inequitable. Among those tested, 34 (8.4%) had ALK-positive NSCLC. ALK-positive disease was more prevalent in younger versus older patients, nonsmokers versus smokers, and in MĀori, Pacific or Asian ethnic groups than in NZ Europeans. FISH, IHC and NGS showed broad concordance for detecting ALK-positive disease under local testing conditions. Among patients with ALK-positive metastatic NSCLC, those treated with ALK TKIs survived markedly longer than those not treated with ALK TKIs (median overall survival 5.12 versus 0.55 years). CONCLUSION:Lung cancer outcomes in NZ may be improved by providing national guidelines and funding policy for ALK testing and access to subsidized ALK TKI therapy. This article is protected by copyright. All rights reserved. en
dc.format.medium Print-Electronic en
dc.language eng en
dc.relation.ispartofseries Internal medicine journal en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri en
dc.title Screening for Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in New Zealand. en
dc.type Journal Article en
dc.identifier.doi 10.1111/imj.14435 en
dc.rights.holder Copyright: The author en
pubs.publication-status Published en
dc.rights.accessrights en
pubs.subtype Journal Article en
pubs.elements-id 777175 en Medical and Health Sciences en Medical Sciences en Pharmacology en Population Health en Epidemiology & Biostatistics en Science en Science Research en Maurice Wilkins Centre (2010-2014) en
dc.identifier.eissn 1445-5994 en
pubs.record-created-at-source-date 2019-07-19 en
pubs.dimensions-id 31318119 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace